November 5, 2025 Tuesday delivered a stark reminder of biotech’s unforgiving nature as Sarepta Therapeutics collapsed 40% following a devastating Duchenne muscular dystrophy confirmatory trial
Healthcare markets delivered a news-heavy session today as mega-deals, regulatory shifts, and compelling clinical data converged to reshape sector dynamics. Thermo Fisher Scientific’s $8.9 billion
Monday delivered a mixed but ultimately positive session for healthcare investors, with strong pharmaceutical earnings and strategic deals offsetting concerns about biotech funding headwinds. Biopharma
Markets experienced significant turbulence this week as banking sector concerns collided with healthcare earnings, policy developments, and robust deal-making activity. Here’s everything you need to
The healthcare sector is experiencing a profound transformation as industry giants restructure, pricing pressures intensify, and strategic acquisitions reshape the competitive landscape. Johnson & Johnson
The obesity drug market is heating up fast, and Pfizer just made a major play. Their acquisition of Metsera for up to $7.3 billion shows
Strategic deal creates diversified specialty company with strong acute care presence and immediate revenue diversification CorMedix Inc. announced the completion of its $300 million acquisition
Exclusive U.S. licensing deal aims to reshape colorectal cancer screening landscape Exact Sciences secured exclusive U.S. commercialization rights to Freenome’s blood-based colorectal cancer screening test
Belgian specialty pharma gains pediatric cancer franchise and FDA priority review voucher Belgian specialty pharmaceutical company SERB Pharmaceuticals announced an all-cash $412 million acquisition of
French pharma giant expands neuroscience pipeline with Boston biotech’s microglial disease expertise Sanofi announced its intention to acquire all remaining shares of Vigil Neuroscience for
